RO-7617991
- Generic Name
- RO-7617991
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
Phase 1
Recruiting
- Conditions
- Refractory CancerRecurrent CancerSolid Tumor, Adult
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06372574
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath